Demographics and baseline characteristics
| Characteristic | dMMR/MSI-H EC (n=108) | MMRp/MSS EC (n=156) |
| Age, median (IQR), years | 64.5 (58.5–69.5) | 64.5 (30–86) |
| Disease status, n (%) | ||
| Advanced | 58 (53.7) | 98 (62.8) |
| Recurrent | 50 (46.3) | 57 (36.5) |
| Unknown | 0 | 1 (0.6) |
| FIGO stage at primary diagnosis, n (%) | ||
| Stage I | 41 (38.0) | 46 (29.5) |
| Stage II | 9 (8.3) | 11 (7.1) |
| Stage III | 38 (35.2) | 43 (27.6) |
| Stage IV | 20 (18.5) | 55 (35.3) |
| Unknown | 0 | 1 (0.6) |
| Histologic subtype, n (%) | ||
| Grade 1 or 2 endometrioid carcinoma | 71 (65.7) | 35 (22.4) |
| Serous | 5 (4.6) | 59 (37.8) |
| Clear cell | 1 (0.9) | 10 (6.4) |
| Squamous | 1 (0.9) | 3 (1.9) |
| Undifferentiated | 4 (3.7) | 3 (1.9) |
| Carcinosarcoma | 0 | 2 (1.3) |
| Mixed carcinoma | 6 (5.6) | 11 (7.1) |
| Type II EC, NOS | 14 (13.0) | 24 (15.4) |
| Adenocarcinoma† | 5 (4.6) | 9 (5.8) |
| Unknown | 1 (0.9) | 0 |
| Prior lines of therapy, n (%)* | ||
| 1 | 69 (63.9) | 72 (46.2) |
| 2 | 27 (25.0) | 67 (42.9) |
| ≥3 | 12 (11.1) | 17 (10.9) |
| Prior radiation, n (%) | 77 (71.3) | 95 (60.9) |
*Includes lines of the therapy in the adjuvant setting.
†Includes adenocarcinoma and adenocarcinoma with ambiguous differentiation
dMMR, mismatch repair deficient; EC, endometrial cancer; FIGO, International Federation of Gynaecology and Obstetrics; MMRp, mismatch repair proficient; MSI-H, microsatellite instability-high; MSS, microsatellite stable; NOS, not otherwise specified.